A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Fulvestrant (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONALEESA-3
- Sponsors Novartis; Novartis Pharma A.G.
- 03 Aug 2016 According to a Novartis media release, this trial is fully enrolled.
- 03 Aug 2016 According to a Novartis media release, status changed from recruiting to active, no longer recruiting.
- 28 Jul 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2020.